RxDoctor Payments Data

Eduardo Gonzalez-Stubbe, MD

Ophthalmology · New Orleans, LANPI 1245508183

Payments from drug & device makers

$1,410in general payments, 2019–2025

Across 24 payments — averaging $58.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Regeneron Healthcare Solutions, Inc.$345
  • Genentech USA, Inc.$312
  • Regeneron$268
  • Bausch & Lomb Americas Inc.$168
  • AbbVie$147
  • Alcon Puerto Rico Inc$77
  • plus $92 from 3 others

What the payments were for

  • Food & beverage$1,39299%
  • Education$181%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Regeneron Healthcare Solutions, Inc.7$345
Genentech USA, Inc.6$312
Regeneron2$268
Bausch & Lomb Americas Inc.3$168
AbbVie2$147
Alcon Puerto Rico Inc1$77
Alcon1$52
Novartis1$21
Amgen1$20

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,410 in reported general payments places this provider in the 40th percentile of 286 ophthalmology providers in Louisiana.

See all ophthalmology providers in Louisiana

Medicare billing

Part B allowed, 2024
$13,178
Medicare patients
38
Services billed
179

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost60$17,002
Prednisolone Acetate403$15,168
Brimonidine Tartrate95$11,086
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol47$7,990
CombiganBrimonidine Tartrate/Timolol34$7,049
RestasisCyclosporine14$6,601
Ketorolac Tromethamine192$4,550
Alphagan PBrimonidine Tartrate23$4,519
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat112$3,679
Atropine Sulfate94$3,512
Fluorometholone39$2,506
Dorzolamide Hcl62$1,887
Latanoprost133$1,773
MoxifloxacinMoxifloxacin Hcl42$1,402
ErythromycinErythromycin Base80$1,248

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Combigan, Restasis, Alphagan P$147$35,172131 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 286 ophthalmology providers in Louisiana.

Other ophthalmology in New Orleans

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →